|Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.|
|PMID: 16820648 Owner: NLM Status: MEDLINE|
|BACKGROUND: Surgical intervention is playing an increasingly important therapeutic role in congestive heart failure (CHF) patients with ischemia and dilated cardiomyopathy. Their mitral regurgitation (MR) is a result of left ventricular (LV) geometrical distortion. The optimal type of ring for CHF patients with geometric ventricular-based MR is unknown. This study reviewed the results of flexible versus nonflexible complete mitral valve rings in CHF patients with geometric mitral regurgitation. METHODS AND RESULTS: Using a prospectively maintained database, patients undergoing mitral valve reconstruction (MVR) with either a flexible or nonflexible complete ring were identified on the basis of preoperative ejection fraction (EF) < or = 30% and no primary mitral pathology. These 2 groups of CHF patients with severe geometric MR were then compared in terms of recurrent MR requiring reoperation. Between 1992 and 2004, 289 patients with EF < or = 30%, received an undersized complete mitral annuloplasty ring as their MVR procedure. Of these, 170 patients had a flexible complete ring. In follow-up, 16 "flexible" patients (9.4%) required a repeat procedure for significant recurrent geometric MR and CHF (10 replacements, 3 re-repairs, 3 transplants). The average time to reoperation was 2.4 years. In contrast, 119 patients with an EF < or = 30% received a MVR using an undersized nonflexible complete ring. Only 3 "non-flexible" patients required a repeat operation, MVR (1), and 2 patients required a transplant. The time to reoperation was 4.0 years. A significant difference in reoperation rates, for recurrent MR, between the 2 groups (P=0.012). There were no differences between groups, in terms of age, ring size used, preoperative EF, LV size, MR grade, or New York Heart Association class. CONCLUSIONS: Patients with CHF having a flexible ring have a higher likelihood of developing recurrent MR requiring reoperation. The use of a nonflexible ring appears to significantly reduce the need for repeat surgical procedures. Further refinement and development of nonflexible ring systems, aimed at LV restoration, deserve ongoing investigation.|
|Martinus T Spoor; Amy Geltz; Steven F Bolling|
Related Documents :
|20031668 - Trans-coronary-venous interventions.
3315668 - Quantification of valvular regurgitation using radioisotopes.
20036158 - Severe aortic regurgitation and reduced left ventricular ejection fraction: outcomes af...
12209288 - Acute effects of non-invasive ventilatory support on functional mitral regurgitation in...
3390768 - Reoperation within 2 years of aortofemoral bypass.
19833308 - Early electrocardiographic findings and mr imaging-verified microvascular injury and my...
|Type: Comparative Study; Evaluation Studies; Journal Article|
|Title: Circulation Volume: 114 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2006 Jul|
|Created Date: 2006-07-05 Completed Date: 2006-08-18 Revised Date: 2007-11-15|
Medline Journal Info:
|Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States|
|Languages: eng Pagination: I67-71 Citation Subset: AIM; IM|
|Section of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan 48109-0348, USA.|
|APA/MLA Format Download EndNote Download BibTex|
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Aspirin / therapeutic use
Cardiomyopathy, Dilated / complications*, pathology
Combined Modality Therapy
Digoxin / therapeutic use
Diuretics / therapeutic use
Drug Therapy, Combination
Heart Failure / drug therapy, etiology, pathology, surgery*, ultrasonography
Heart Ventricles / pathology*
Milrinone / therapeutic use
Mitral Valve / surgery*
Mitral Valve Insufficiency / etiology, surgery*
Norepinephrine / therapeutic use
Postoperative Complications / epidemiology
Spironolactone / therapeutic use
Tricuspid Valve Insufficiency / complications, surgery
|0/Angiotensin-Converting Enzyme Inhibitors; 0/Diuretics; 20830-75-5/Digoxin; 50-78-2/Aspirin; 51-41-2/Norepinephrine; 52-01-7/Spironolactone; 78415-72-2/Milrinone|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Optimal medical therapy is superior to transplantation for the treatment of class I, II, and III hea...
Next Document: Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle.